



ABIVAX to present at the Biotech Showcase during the JP Morgan Healthcare Conference

December 17, 2015

Paris, France, December 17th, 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its CEO, Prof. Hartmut Ehrlich, M.D., will present at the Biotech Showcase™ Annual Conference, to be held in San Francisco on January 11-13, 2016.